Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3137204 | 0.97 | ADH1B (0.39) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4653000 | 0.97 | ADH1B (0.32) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL8670105 | 0.97 | ADH1B (0.32) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10528749 | 0.94 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3636058 | 0.94 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4654343 | 0.94 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11407090 | 0.94 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4578985 | 0.92 | — | — | |
| SCHEMBL1758252 | 0.92 | — | — | |
| SCHEMBL5463726 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776012-A1 | AMINOCARBONYL-SUBSTITUTED THIENSULPHONYLAMINO (THIO) CARBONYLTRIAZOLIN (THI) ONES METHODS FOR PRODUCTION AND USE THEREOF | Bayer CropScience Aktiengesellschaft (DE) | 2007-04-25 | — | — | EP | claimed |
| WO-2006012983-A1 | AMINOCARBONYL-SUBSTITUTED THIENSULPHONYLAMINO (THIO) CARBONYLTRIAZOLIN (THI) ONES METHODS FOR PRODUCTION AND USE THEREOF | BAYER CROPSCIENCE AG (DE) | 2006-02-09 | — | — | WO | claimed |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| EP-2168580-B1 | REMEDY OR PREVENTIVE FOR SCHIZOPHRENIA | TORAY INDUSTRIES (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-8183256-B2 | Remedy or preventive for integration dysfunction syndrome | TORAY INDUSTRIES, INC. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20100160364-A1 | REMEDY OR PREVENTIVE FOR INTEGRATION DYSFUNCTION SYNDROME | TORAY INDUSTRIES, INC. (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2168580-A1 | REMEDY OR PREVENTIVE FOR INTEGRATION DYSFUNCTION SYNDROME | Toray Industries, Inc. (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-20070244081-A1 | TRITERPENE QUATERNARY SALTS AS BIOLOGICALLY ACTIVE SURFACTANTS | REGENTS OF THE UNIVERSITY OF MINNESTOA | 2007-10-18 | — | — | US | disclosed |
| US-7235668-B2 | Process for the preparation of thioalkylamine derivatives | BAYER CROPSCIENCE AG (DE) | 2007-06-26 | — | — | US | disclosed |
| EP-1599465-A1 | SUBSTITUTED N-ARYL NITROGEN HETEROCYCLES | Bayer CropScience AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20050182275-A1 | Process for the preparation of thioalkylamine derivatives | BAYER CORPSCIENCE AG (DE) | 2005-08-18 | — | — | US | disclosed |
| EP-1504005-A2 | SUBSTITUTED PYRAZOLO-PYRIMIDINE-4-ONES | Bayer CropScience AG (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-6838415-B1 | Substituted benzoylisoxazoles and the use thereof as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2005-01-04 | — | — | US | disclosed |
| WO-2004074274-A1 | SUBSTITUTED N-ARYL NITROGEN HETEROCYCLES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | WO | disclosed |
| WO-2003093269-A2 | SUBSTITUTED PYRAZOLO-PYRIMIDINE-4-ONES | BAYER CROPSCIENCE AG (DE) | 2003-11-13 | — | — | WO | disclosed |
| EP-0139388-B1 | PYRROLIZIDINONES AND INDOLIZIDONES | THE UPJOHN COMPANY (US) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160364-A1 | REMEDY OR PREVENTIVE FOR INTEGRATION DYSFUNCTION SYNDROME | GAP43, GRIN2A, GRIN1 | ADH1B 613/4885ADH1C 338/4885ADH1A 199/4885 |
| US-20050182275-A1 | Process for the preparation of thioalkylamine derivatives | TST, OPRM1, TMT1A | ADH1B 275/4885ADH1C 174/4885ADH1A 88/4885 |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | ADH1B 3176/4885ADH1C 2664/4885ADH1A 3493/4885 |
| US-20070244081-A1 | TRITERPENE QUATERNARY SALTS AS BIOLOGICALLY ACTIVE SURFACTANTS | BET1, PGGT1B, RABGGTB | ADH1B 4844/4885ADH1C 4719/4885ADH1A 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.